**Core Concept**
Atypical mycobacteria, also known as non-tuberculous mycobacteria (NTM), are a diverse group of bacteria that can cause infections in humans. These bacteria are resistant to conventional antitubercular agents and require specific antibiotics for treatment. The primary goal is to identify an effective antibiotic that can combat these resistant organisms.

**Why the Correct Answer is Right**
The correct answer is a fluoroquinolone antibiotic, specifically moxifloxacin. This antibiotic works by inhibiting bacterial DNA gyrase and topoisomerase IV, essential enzymes for bacterial DNA replication and transcription. Moxifloxacin's broad-spectrum activity includes efficacy against atypical mycobacteria, making it a preferred choice for treating NTM infections.

**Why Each Wrong Option is Incorrect**
**Option A:** Isoniazid is a primary antitubercular agent effective against Mycobacterium tuberculosis but is not active against atypical mycobacteria. It works by inhibiting mycolic acid synthesis in M. tuberculosis.
**Option B:** Ethambutol is another antitubercular agent that can be used in combination with isoniazid to treat M. tuberculosis infections. However, it is not effective against atypical mycobacteria.
**Option C:** Rifampicin is a potent antitubercular agent that inhibits RNA synthesis in M. tuberculosis. It is not active against atypical mycobacteria.

**Clinical Pearl / High-Yield Fact**
When treating atypical mycobacterial infections, it is essential to culture the specific organism to determine the most effective antibiotic regimen. Fluoroquinolones, such as moxifloxacin, are often used in combination with other antibiotics to achieve optimal treatment outcomes.

**Correct Answer:** C. Moxifloxacin.